Precision Medicine Online13 天
Arbor Biotechnologies Raises $73.9M in Series C Funding to Advance Gene-Editing Drugs
The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.